The NASH Dash: Analysis Of The Non-Alcoholic Steatohepatitis (NASH) Drug Pipeline & Market

Over the last decade, NASH has remained a graveyard for drug development. To date, there are no disease-specific approved therapies on the market. Companies in the dash for a NASH breakthrough may require strategic repositioning to maximize asset value in the near-term. In our latest white paper, Back Bay Life Science Advisors analyzed the opportunities and challenges ahead for companies seeking a NASH breakthrough. 

We looked at the first and second wave of NASH drugs poised to change the NASH management paradigm and shape pricing and reimbursement. Back Bay also examined the NASH M&A and transaction landscape to identify trends for companies looking to build a NASH pipeline. 

This white paper also explores the potential market access dynamics that will complicate commercial success for novel NASH assets, considering the lack of marketed analogs and ambiguity over clinical relevance of surrogate endpoints.